Abstract
Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC). We performed a pan-tumor analysis of the incidence and characteristics of ROS1 fusions across all solid tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
